Clinical effect of Epalrestat in the treatment of diabetic peripheral neuropathy
GOU Chongyang1 ZHANG Jinchao2 ZHANG Xiuyuan1▲
1.Endocrinology Department, Shunyi Hospital, Beijing Hospital of Traditional Chinese Medicine, Beijing 101300, China;
2.Beijing Hospital of Traditional Chinese Medicine Research Institute Affiliated to Capital Medical University, Beijing 100010, China
Abstract：Objective To observe the effects of Epalrestat in the treatment of diabetic peripheral neuropathy. Methods One hundred and twenty-three cases of patients with diabetic peripheral neuropathy admitted to Shunyi Hospital, Beijing Hospital of Traditional Chinese Medicine from February 2014 to December 2016 were selected and divided into control group, observation group and combined group by random table method, with 41 cases in each group. The control group was given Mecobalamin Tablets, the observation group was given Epalrestat Capsules, while the combined group was given Mecobalamin Tablets combined with Epalrestat Capsules. All three groups were treated for 12 weeks. Michigan neurological screening scale (MNSI) was used to evaluate the symptoms and signs of neuropathy. The electromyography was used to detect the nerve conduction velocity of exercise and sensory nerves in median nerve, nervus peroneus communis, ulnar nerve before and after treatment. The conditions of adverse reactions were recorded. Results After treatment, the scores of symptoms and signs of neuropathy of MNSI in the three groups were all lower than those before treatment (P ＜ 0.05), which of observation group and combined group were all lower than those of control group (P ＜ 0.05), while there were no statistically significant difference between observation group and combined group (P ＞ 0.05). After treatment, the nerve conduction velocity of exercise and sensory nerves in median nerve, nervus peroneus communis, ulnar nerve in the three groups were all faster than those before treatment (P ＜ 0.05), which of observation group and combined group were all faster than those of control group (P ＜ 0.05), while there were no statistically significant differences between observation group and combined group (P ＞ 0.05). There were no serious adverse reactions in the three groups. Conclusion Compared with Mecobalamin, Epalrestat can improve the symptoms, signs and nerve conduction velocity more effectively, and good safety, but combined treatments of the two drugs don′t show better efficacy.
2019, Vol. 16 
京公网安备 11010502046598号